



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Liggett et al.

Attorney Docket: 13105

Serial No.: 09/692,077

Examiner: Unassigned

Dated Filed: October 19, 2000

Group Art Unit: 1614

For: Alpha-2B-adrenergic receptor polymorphisms

Kalow & Springut, LLP
488 Madison Avenue, 19th Floor
New York, NY 10022

Date: March 16, 2001

Assistant Commissioner for Patents
Washington, DC 20231

AMENDMENT

Sir:

This amendment provides substitute sequence listings in response to the Raw Sequence Listing Error Report.

IN THE SPECIFICATION:

Please remove the original sequence listing (pages 1-6) and insert the enclosed substitute sequence listing (pages 1-8).

REMARKS

Applicants enclose a paper copy of substitute sequence listings showing SEQ ID NOs: 1-23. A copy of the substitute sequence listing in computer-readable form on 3.5-inch diskette is also enclosed. By this amendment, applicants replace the original sequence listing with the substitute sequence listing.

Certificate of Express Mail Under 37 C.F.R. 1.10

I hereby declare that this correspondence is being deposited with the United States Postal Service via Express Mail Label No. EL60553345345 in an envelope addressed to:
Commissioner of Patents and Trademarks, Washington, DC 20231

3/16/01
Date

J. Colwell
Name